The stock's fall snapped a three-day winning streak.

Zoetis's leadership, scale, and innovation position it well against new competitors. Click here to read more about ZTS stock ...

Investing in attractive dividend growth stocks can lead to superior long-term returns. The two healthcare companies below ...

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal ...

Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Tuesday, August 5, 2025. Chief Executive ...

Zoetis delivered revenue and adjusted EPS above Wall Street expectations in Q1, driven by strong organic operational growth across its diverse portfolio. Management pointed to particularly robust ...

Zoetis, a leading animal health company, has shown impressive growth with a 17.55% CAGR since its IPO. Read why I rate ZTS stock a Buy now.

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. Featuring daily updates of ...

Zoetis said its first-quarter earnings rose 11% as the animal-medicine maker reported strong sales in the U.S. and a lower cost of sales. Animal-Medicine Maker Backs 2014 Financial Outlook.

Animal-medicine maker Zoetis raised about $2.2 billion in an initial public offering, the largest IPO deal from a U.S. company since Facebook debuted last May. Zoetis shares are expected to begin ...